ASH 2020 | Upfront ASCT vs bortezomib-based intensification therapy in newly diagnosed myeloma
Michele Cavo, MD, PhD, Bologna University School of Medicine, Bologna, Italy, presents the findings from a long-term follow-up of the multicenter Phase III EMN02/HO95 study (NCT01208766), which compared bortezomib-melphalan-prednisone (VMP) intensification with upfront autologous stem cell transplant in newly diagnosed multiple myeloma. The results from almost 1200 patients found that at a median follow up of 75 months, the ASCT arm had significantly improved overall survival (OS) compared to those treated with VMP. Progression free survival (PFS) and time to next treatment were also significantly prolonged. ASCT was particularly beneficial for individuals with high-risk disease features, including R-ISS stage 2-3 disease, cytogenetic abnormalities, and notably del(17p)-positivity. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
